Reason for request
Inclusion
No clinical benefit demonstrated in dual therapy with metformin or in triple therapy with metformin/sulfonylurea or metformin/insulin in the management of type 2 diabetic patients inadequately controlled with metformin, or with a combination of metformin and a sulfonylurea or metformin and insulin
No clinical benefit in monotherapy or in dual therapy with a sulfonylurea or insulin
- JARDIANCE has Marketing Authorisation in the treatment of type 2 diabetes in monotherapy and in combination with other blood glucose-lowering medicinal products, including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
- The available clinical data are based mainly on studies versus placebo, whereas active comparators do exist. Just one study has shown modest efficacy for JARDIANCE 25 mg/day versus glimepiride (sulfonylurea) 1-4 mg/day whereas its maximum dose is 6 mg/day.
Clinical Benefit
| Moderate |
Monotherapy : Insufficient for reimbursement by National Health Insurance
Dual therapy :
- with metformin : Moderate
Tritherapy :
- with metformin and a sulfonylurea : Moderate
- with insulin and metformin : Moderate |
| Insufficient |
- with a sulfonylurea : Insufficient for reimbursement by National Health Insurance
- with insulin : Insufficient for reimbursement by National Health Insurance |
Clinical Added Value
| no clinical added value |
In the indications as dual therapy with metformin, and as tritherapy with metformin and a sulfonylurea or with metformin and insulin :
In light of the available clinical data, namely placebo-controlled studies with empagliflozin 10 or 25 mg/day when active comparators are available and modest
results from a sequential non-inferiority and superiority study of empagliflozin at its maximum dose of 25 mg/day versus an active comparator, the sulfonylurea glimepiride, at doses of 1 to 4 mg/day (whereas its maximum dose is 6 mg/day), the Committee considers that the JARDIANCE proprietary medicinal products do not provide any improvement in actual benefit (level V, non-existent) in the management of patients with poorly controlled type 2 diabetes, as dual oral therapy in combination with metformin and as tritherapy in combination with metformin and a sulfonylurea or with metformin and insulin.
In the indications as monotherapy, and as dual therapy with sulfonylureas or insulin : Not applicable. |
| Not applicable |
|
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
gJd8cCfzJTYkbZv4
